Neuraxis Inc (NRXS)
AMEXHealth CareBiotechnologySnapshot 2026-09-09
$5.73-3.05%
Close 2026-09-09 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Neuraxis grew revenue from $0.97M in 2025-Q4 to $1.6M in 2026-Q1. The company expects $1.6M revenue in 2026-Q1. Cash reserves are about $7.1M to support operations.
Neuraxis is still loss-making with operating losses near $1.7M in 2026-Q1. Earnings estimates remain negative through 2027. The recent share price dropped 19% from highs.
The price is about 38% above our fair value near $5. Analysts expect 24% revenue growth. Our view is cautious given ongoing losses and weak earnings.
Breaks if: cash falls below $5 million in 2026-Q1
Breaks if: operating loss worsens beyond -$2.1 million in 2026-Q1
Breaks if: revenue falls below $1.0 million in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but shows potential for revenue growth, making it a high-risk, high-reward situation.
The market appears to have a low fragility tier, indicating that it does not expect significant volatility. However, NRXS is priced at a premium compared to its peers, which suggests that investors may have high expectations for future performance.
Management has prioritized increasing revenue and maintaining cash reserves, with recent revenue growth indicating some success. However, operating losses have increased, suggesting challenges in managing costs.
The long-term thesis hinges on management's ability to deliver on revenue growth while controlling losses. Additionally, external factors such as sector performance and economic conditions will significantly impact NRXS's trajectory.
The most important moves since the prior daily snapshot.
Company momentum rose by 50.0 points (from 30.0 to 80.0).
Composite insight rose by 10.4 points (from 12.2 to 22.6).
Yes, our read has strengthened. Revenue growth significantly exceeded expectations, which supports a positive outlook. There are no new threats identified that could weaken this view.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, NRXS is in a watch state as it faces both opportunities and challenges in the coming months. Not investment advice.